<p>Genmab A/S 赞助的 ADR (NASDAQ:GMAB - 获取免费报告) 的股价在周二的交易中达到了新的 52 周高点。该公司的股价最高达到 $33.67，最后交易于 $33.65，成交量为 1371892 股。该股票之前收于 $33.06。</p>
<h2>分析师设定新的价格目标</h2>
<p>多家研究公司最近对 GMAB 发布了报告。华尔街禅在 11 月 22 日的报告中将 Genmab A/S 的评级从 “持有” 上调至 “买入”。Truist Financial 在 11 月 6 日的研究报告中重申了 “买入” 评级，并对 Genmab A/S 的股票设定了 $48.00 的目标价（低于之前的 $49.00）。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Genmab A/S 股票的 “持有 (c)” 评级。Guggenheim 在 9 月 23 日的报告中将 Genmab A/S 的股票评级从 “中性” 上调至 “买入”，并设定了 $43.00 的价格目标。最后，Zacks Research 在 10 月 31 日的研究报告中将 Genmab A/S 的股票评级从 “强力买入” 下调至 “持有”。一位投资分析师对该股票给予了强力买入评级，六位分析师给予了买入评级，三位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Genmab A/S 的共识评级为 “适度买入”，平均目标价为 $39.75。</p>
<p><strong>查看我们关于 GMAB 的最新报告</strong></p>
<h2>Genmab A/S 股价上涨 1.8%</h2>
<p>该公司的市值为 216.2 亿美元，市盈率为 14.32，市盈增长比率为 1.69，贝塔值为 0.90。该公司的 50 日移动平均价格为 $30.77，200 日移动平均价格为 $26.80。</p>
<p>Genmab A/S (NASDAQ:GMAB - 获取免费报告) 最近于 11 月 6 日发布了季度财报。该公司报告本季度每股收益为 $0.65，超出市场共识预期的 $0.48，超出幅度为 $0.17。该公司本季度的收入为 10.2 亿美元，而分析师预期为 9.754 亿美元。Genmab A/S 的净利润率为 41.36%，股本回报率为 23.98%。整体来看，研究分析师预计 Genmab A/S 赞助的 ADR 本年度将发布 1.45 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近买入和卖出了 GMAB 的股票。摩根大通在第二季度增持了 Genmab A/S 的股份，增幅为 17.0%。摩根大通现在拥有 933,309 股该公司的股票，价值 19,282,000 美元，此前在上个季度又购买了 135,814 股。Foresight Group Ltd Liability Partnership 在第一季度购买了 Genmab A/S 的新股份，价值约为 954,000 美元。Squarepoint Ops LLC 在第二季度增持了 Genmab A/S 的股份，增幅为 636.3%。Squarepoint Ops LLC 现在拥有 94,233 股该公司的股票，价值 1,947,000 美元，此前在上个季度又收购了 81,434 股。Vident Advisory LLC 在第一季度购买了 Genmab A/S 的新股份，价值约为 242,000 美元。最后，Wealth Enhancement Advisory Services LLC 在第二季度收购了 Genmab A/S 的新股份，价值约为 257,000 美元。7.07% 的股票由机构投资者和对冲基金持有。</p>
<h2>Genmab A/S 公司简介</h2>
<p>(获取免费报告)</p>
<p>Genmab A/S 是一家总部位于丹麦的生物技术公司，专注于抗体治疗药物的发现和开发，以治疗癌症。自 1999 年成立以来，总部位于哥本哈根的 Genmab 建立了一个强大的研究平台，专注于利用新型抗体工程技术创造下一代疗法。该公司的工作重点是识别血液恶性肿瘤和实体肿瘤中的靶点，将其专有分子从早期发现推进到临床开发。</p>
<p>Genmab 的产品组合包括与全球领先制药合作伙伴共同开发的产品。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Genmab A/S</li>
<li>请勿删除，请立即阅读</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>投资者警报：微小的 “$3 人工智能奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Genmab A/S 吗？</h2>
<p>在你考虑 Genmab A/S 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Genmab A/S 并不在名单上。</p>
<p>虽然 Genmab A/S 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

GMAB

<p>Genmab A/S（纳斯达克代码：GMAB）达到了新的 52 周高点，价格为 33.67 美元。分析师的评级各不相同，普遍共识为 “适度买入”，平均目标价为 39.75 美元。该公司报告了强劲的季度收益，超出预期，每股收益为 0.65 美元，收入为 10.2 亿美元。机构投资者正在积极交易该股票，市值为 216.2 亿美元</p>

<p>Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $33.67 and last traded at $33.65, with a volume of 1371892 shares. The stock had previously closed at $33.06.</p>
<div class="lb-trans"><p>Genmab A/S 赞助的 ADR (NASDAQ:GMAB - 获取免费报告) 的股价在周二的交易中达到了新的 52 周高点。该公司的股价最高达到 $33.67，最后交易于 $33.65，成交量为 1371892 股。该股票之前收于 $33.06。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of research firms recently issued reports on GMAB. Wall Street Zen raised Genmab A/S from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 22nd. Truist Financial reaffirmed a &#34;buy&#34; rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Guggenheim raised shares of Genmab A/S from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $43.00 price target for the company in a report on Tuesday, September 23rd. Finally, Zacks Research cut shares of Genmab A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $39.75.</p>
<div class="lb-trans"><p>多家研究公司最近对 GMAB 发布了报告。华尔街禅在 11 月 22 日的报告中将 Genmab A/S 的评级从 “持有” 上调至 “买入”。Truist Financial 在 11 月 6 日的研究报告中重申了 “买入” 评级，并对 Genmab A/S 的股票设定了 $48.00 的目标价（低于之前的 $49.00）。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Genmab A/S 股票的 “持有 (c)” 评级。Guggenheim 在 9 月 23 日的报告中将 Genmab A/S 的股票评级从 “中性” 上调至 “买入”，并设定了 $43.00 的价格目标。最后，Zacks Research 在 10 月 31 日的研究报告中将 Genmab A/S 的股票评级从 “强力买入” 下调至 “持有”。一位投资分析师对该股票给予了强力买入评级，六位分析师给予了买入评级，三位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Genmab A/S 的共识评级为 “适度买入”，平均目标价为 $39.75。</p>
</div><p><strong>Check Out Our Latest Report on GMAB</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GMAB 的最新报告</strong></p>
</div><h2>Genmab A/S Trading Up 1.8%</h2>
<div class="lb-trans"><h2>Genmab A/S 股价上涨 1.8%</h2>
</div><p>The company has a market cap of $21.62 billion, a price-to-earnings ratio of 14.32, a price-to-earnings-growth ratio of 1.69 and a beta of 0.90. The firm's fifty day moving average price is $30.77 and its 200-day moving average price is $26.80.</p>
<div class="lb-trans"><p>该公司的市值为 216.2 亿美元，市盈率为 14.32，市盈增长比率为 1.69，贝塔值为 0.90。该公司的 50 日移动平均价格为 $30.77，200 日移动平均价格为 $26.80。</p>
</div><p>Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. As a group, research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.</p>
<div class="lb-trans"><p>Genmab A/S (NASDAQ:GMAB - 获取免费报告) 最近于 11 月 6 日发布了季度财报。该公司报告本季度每股收益为 $0.65，超出市场共识预期的 $0.48，超出幅度为 $0.17。该公司本季度的收入为 10.2 亿美元，而分析师预期为 9.754 亿美元。Genmab A/S 的净利润率为 41.36%，股本回报率为 23.98%。整体来看，研究分析师预计 Genmab A/S 赞助的 ADR 本年度将发布 1.45 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently bought and sold shares of GMAB. JPMorgan Chase &amp; Co. grew its stake in Genmab A/S by 17.0% during the second quarter. JPMorgan Chase &amp; Co. now owns 933,309 shares of the company's stock worth $19,282,000 after buying an additional 135,814 shares in the last quarter. Foresight Group Ltd Liability Partnership bought a new stake in shares of Genmab A/S during the 1st quarter worth approximately $954,000. Squarepoint Ops LLC boosted its position in shares of Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company's stock worth $1,947,000 after acquiring an additional 81,434 shares in the last quarter. Vident Advisory LLC bought a new position in Genmab A/S in the first quarter valued at approximately $242,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Genmab A/S during the second quarter valued at approximately $257,000. 7.07% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了 GMAB 的股票。摩根大通在第二季度增持了 Genmab A/S 的股份，增幅为 17.0%。摩根大通现在拥有 933,309 股该公司的股票，价值 19,282,000 美元，此前在上个季度又购买了 135,814 股。Foresight Group Ltd Liability Partnership 在第一季度购买了 Genmab A/S 的新股份，价值约为 954,000 美元。Squarepoint Ops LLC 在第二季度增持了 Genmab A/S 的股份，增幅为 636.3%。Squarepoint Ops LLC 现在拥有 94,233 股该公司的股票，价值 1,947,000 美元，此前在上个季度又收购了 81,434 股。Vident Advisory LLC 在第一季度购买了 Genmab A/S 的新股份，价值约为 242,000 美元。最后，Wealth Enhancement Advisory Services LLC 在第二季度收购了 Genmab A/S 的新股份，价值约为 257,000 美元。7.07% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Genmab A/S Company Profile</h2>
<div class="lb-trans"><h2>Genmab A/S 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.</p>
<div class="lb-trans"><p>Genmab A/S 是一家总部位于丹麦的生物技术公司，专注于抗体治疗药物的发现和开发，以治疗癌症。自 1999 年成立以来，总部位于哥本哈根的 Genmab 建立了一个强大的研究平台，专注于利用新型抗体工程技术创造下一代疗法。该公司的工作重点是识别血液恶性肿瘤和实体肿瘤中的靶点，将其专有分子从早期发现推进到临床开发。</p>
</div><p>Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.</p>
<div class="lb-trans"><p>Genmab 的产品组合包括与全球领先制药合作伙伴共同开发的产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Genmab A/S</li>
<li>Do not delete, read immediately</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Genmab A/S</li>
<li>请勿删除，请立即阅读</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>投资者警报：微小的 “$3 人工智能奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Genmab A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Genmab A/S 吗？</h2>
</div><p>Before you consider Genmab A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Genmab A/S 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Genmab A/S 并不在名单上。</p>
</div><p>While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Genmab A/S 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Genmab A/S（NASDAQ:GMAB）创下一年新高 - 现在仍然值得购买吗？